Suppr超能文献

伴有或不伴有自体静脉的下肢严重缺血的股腘动脉重建术的经济学分析

The economics of femorocrural reconstruction for critical leg ischemia with and without autologous vein.

作者信息

Cheshire N J, Wolfe J H, Noone M A, Davies L, Drummond M

机构信息

St. Mary's Hospital, London, England.

出版信息

J Vasc Surg. 1992 Jan;15(1):167-74; discussion 174-5. doi: 10.1067/mva.1992.33676.

Abstract

It is well established that primary arterial reconstruction, even to crural vessels, is cheaper than amputation. Reintervention increases expenditure and may produce mean costs exceeding those of primary amputation. Furthermore, secondary amputation may eventually become necessary. Femorocrural grafts have the highest average "reconstruction policy" cost (i.e., primary procedure and all further operations necessary during follow-up). We must therefore seek support for this potentially expensive form of treatment. In conjunction with health economists we have compared the average policy cost of 130 reconstructions with grafts exceeding 70 cm in length (89 vein grafts, 41 polytetrafluoroethylene grafts with a distal vein collar) with 67 vascular amputations, at mean follow-up of 3 years. One-month mortality rate after reconstruction was less than 1% but was 10% after amputation. At 3 years, however, 20% of both groups were dead. Overall 3-year patency is 65% (72% for vein grafts, 48% for polytetrafluoroethylene grafts). Ninety-seven percent of irreversible graft occlusions resulted in amputation in these patients. After autologous vein grafting reintervention, our follow-up showed increased mean costs from $6898 to $15,024 per patient. After prosthetic grafting, the higher reintervention rate increased from $6898 to $20,416. These mean costs remained less than amputation, reintervention, and additional mobility costs, which amounted to a mean of $21,726 per patient. Important differences in outcome were observed: 70% of patients undergoing amputation were confined to the home compared with only 9% of patients undergoing reconstruction; 30% of patients undergoing amputation were confined to bed or had to use a wheelchair compared with 1% of patients undergoing reconstruction.

摘要

众所周知,原发性动脉重建术,即使是针对小腿血管的重建,也比截肢术成本更低。再次干预会增加费用,且可能使平均成本超过原发性截肢术。此外,二次截肢最终可能仍有必要。股腘动脉移植物的平均“重建策略”成本最高(即初次手术及随访期间所有必要的进一步手术)。因此,我们必须为这种可能成本高昂的治疗方式寻求支持。我们与卫生经济学家合作,比较了130例长度超过70厘米的移植物重建术(89例静脉移植物,41例带远端静脉套环的聚四氟乙烯移植物)与67例血管截肢术的平均策略成本,平均随访时间为3年。重建术后1个月死亡率低于1%,但截肢术后为10%。然而,3年后,两组的死亡率均为20%。总体3年通畅率为65%(静脉移植物为72%,聚四氟乙烯移植物为48%)。在这些患者中,97%的不可逆移植物闭塞导致了截肢。自体静脉移植再次干预后,我们的随访显示每位患者的平均成本从6898美元增加到15024美元。人工血管移植后,更高的再次干预率使成本从6898美元增加到20416美元。这些平均成本仍低于截肢、再次干预及额外的行动成本,后者平均每位患者为21726美元。观察到了结局方面的重要差异:接受截肢术的患者中有7%只能居家,而接受重建术的患者中这一比例仅为9%;接受截肢术的患者中有30%只能卧床或必须使用轮椅,而接受重建术的患者中这一比例为1%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验